NAMS
Price
$35.65
Change
-$0.30 (-0.83%)
Updated
Dec 24 closing price
Capitalization
4.04B
69 days until earnings call
Intraday BUY SELL Signals
ROIV
Price
$22.50
Change
+$0.05 (+0.22%)
Updated
Dec 24 closing price
Capitalization
15.65B
53 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NAMS vs ROIV

Header iconNAMS vs ROIV Comparison
Open Charts NAMS vs ROIVBanner chart's image
NewAmsterdam Pharma
Price$35.65
Change-$0.30 (-0.83%)
Volume$310.43K
Capitalization4.04B
Roivant Sciences
Price$22.50
Change+$0.05 (+0.22%)
Volume$3.72M
Capitalization15.65B
NAMS vs ROIV Comparison Chart in %
View a ticker or compare two or three
VS
NAMS vs. ROIV commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NAMS is a Hold and ROIV is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (NAMS: $35.65 vs. ROIV: $22.50)
Brand notoriety: NAMS and ROIV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NAMS: 31% vs. ROIV: 44%
Market capitalization -- NAMS: $4.04B vs. ROIV: $15.65B
NAMS [@Biotechnology] is valued at $4.04B. ROIV’s [@Biotechnology] market capitalization is $15.65B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NAMS’s FA Score shows that 1 FA rating(s) are green whileROIV’s FA Score has 0 green FA rating(s).

  • NAMS’s FA Score: 1 green, 4 red.
  • ROIV’s FA Score: 0 green, 5 red.
According to our system of comparison, NAMS is a better buy in the long-term than ROIV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NAMS’s TA Score shows that 4 TA indicator(s) are bullish while ROIV’s TA Score has 4 bullish TA indicator(s).

  • NAMS’s TA Score: 4 bullish, 4 bearish.
  • ROIV’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NAMS is a better buy in the short-term than ROIV.

Price Growth

NAMS (@Biotechnology) experienced а +5.85% price change this week, while ROIV (@Biotechnology) price change was -0.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

NAMS is expected to report earnings on Mar 04, 2026.

ROIV is expected to report earnings on Feb 16, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ROIV($15.6B) has a higher market cap than NAMS($4.04B). ROIV YTD gains are higher at: 90.194 vs. NAMS (38.716). NAMS has higher annual earnings (EBITDA): -268.03M vs. ROIV (-1.14B). ROIV has more cash in the bank: 4.39B vs. NAMS (703M). NAMS has less debt than ROIV: NAMS (266K) vs ROIV (98.8M). NAMS has higher revenues than ROIV: NAMS (35.2M) vs ROIV (20.3M).
NAMSROIVNAMS / ROIV
Capitalization4.04B15.6B26%
EBITDA-268.03M-1.14B23%
Gain YTD38.71690.19443%
P/E RatioN/A1.97-
Revenue35.2M20.3M173%
Total Cash703M4.39B16%
Total Debt266K98.8M0%
TECHNICAL ANALYSIS
Technical Analysis
NAMSROIV
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
69%
Momentum
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
67%
MACD
ODDS (%)
Bearish Trend 2 days ago
48%
Bullish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
58%
Bearish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
53%
Bullish Trend 2 days ago
67%
Advances
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
74%
Declines
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 8 days ago
69%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
64%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
NAMS
Daily Signal:
Gain/Loss:
ROIV
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RNGAX60.420.26
+0.43%
American Funds New Economy R1
LCSTX27.570.08
+0.29%
ClearBridge Sustainability Leaders FI
VDSYX24.550.05
+0.20%
Victory Diversified Stock Y
SMVFX11.270.02
+0.18%
Virtus Ceredex Mid-Cap Value Equity C
BFGIX61.59-0.07
-0.11%
Baron Focused Growth Institutional

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with IDYA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
-0.83%
IDYA - NAMS
47%
Loosely correlated
+0.76%
IMVT - NAMS
46%
Loosely correlated
+0.45%
CRNX - NAMS
45%
Loosely correlated
-0.33%
ROIV - NAMS
43%
Loosely correlated
+0.22%
XENE - NAMS
41%
Loosely correlated
+1.06%
More

ROIV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ROIV has been loosely correlated with IMVT. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if ROIV jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ROIV
1D Price
Change %
ROIV100%
+0.22%
IMVT - ROIV
61%
Loosely correlated
+0.45%
RVMD - ROIV
50%
Loosely correlated
+1.15%
CRNX - ROIV
48%
Loosely correlated
-0.33%
XENE - ROIV
46%
Loosely correlated
+1.06%
IDYA - ROIV
46%
Loosely correlated
+0.76%
More